2923-LB: A Remote Program for Navigator- and Pharmacist-Led Implementation of Obesity Medications
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2923-lb ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JOHN OSTROMINSKI und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: There is urgent need for effective and scalable obesity care strategies. We evaluated whether a remote, algorithmic, navigator- and pharmacist-led program enhances obesity medication (OM) implementation.
Methods
Participants were recruited via survey from an ongoing program evaluating a digital lifestyle intervention (RestoreHealth). Eligibility criteria included 1) BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with ≥1 obesity-related condition; 2) no current use of OMs; and 3) either an increase in body weight by 3 months, or <3.2 kg body weight reduction by 6 months, after initiation of RestoreHealth. Persons eligible for but declined the OM intervention served as a control group. OMs were prescribed by a pharmacist. The primary outcome was OM prescription over a maximum of 9 months.
Results
Of 200 survey respondents, 99 were eligible (mean age, 50±12 years; mean BMI, 36±6 kg/m2). Of these, 75 (76%) enrolled in the OM intervention and 24 (24%) continued with RestoreHealth alone. Overall, 93.3% of the participants in the OM intervention, vs. 8.3% of control participants, received ≥1 OM prescription (Pcomparsion<0.001). GLP-1RA-based therapies were most prescribed. Participants receiving the OM intervention were more likely to initiate ≥1 OMs and had greater body weight reduction after 6 months vs. control (Figure).
Conclusion
Remote management of OMs by navigators and pharmacists may represent an effective and scalable strategy to improve obesity care. Disclosure J. Ostrominski: Advisory Panel; Current; Corcept Therapeutics. K.B. Wagholikar: None. B.E. Falahee: None. M. Tucci: None. H. Nichols: Advisory Panel; Current; ReCor Medical, Inc. Consultant; Ended; Elsevier. C. Cannon: Research Support; Current; Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk. Other - Research Grants from: Amgen, Better Therapeutics, Boehringer-Ingelheim (BI), Novo Nordisk, and salary support from Colorado Prevention Center (CPC) Clinical Research, which gets research grant support from Amgen, Bayer, Cleerly, Esperion, Lexicon, Silence.; Current; Research Grants from: Amgen, Better Therapeutics, Boehringer-Ingelheim (BI), Novo Nordisk, and salary support from Colorado Prevention Center (CPC) Clinical Research, which gets research grant support. Consultant; Current; Amgen Inc., Amryt Pharma Plc, Applied Therapeutics, Boehringer Ingelheim International GmbH. Other - Consulting fees from Amryt/Chiesi, Amgen, Applied Therapeutics, BI, BMS, CSL Behring, Genomadix, Lilly, Janssen, Milestone, Novartis, Pfizer, Rhoshan, Tremeau; Current; Consulting fees from Amryt/Chiesi, Amgen, Applied Therapeutics, BI, BMS, CSL Behring, Genomadix, Lilly, Janssen, Milestone, Novartis, Pfizer, Rhoshan, Tremeau. Other - I serve on Data and Safety Monitoring Boards for the Areteia, Cortera, Novartis, Novo Nordisk, ROMTherapy, Inc. and the Veterans Administration.; Current; I serve on Data and Safety Monitoring Boards for the Areteia, Cortera, Novartis, Novo Nordisk, ROMTherapy, Inc. and the Veterans Administration. J. Plutzky: Consultant; Current; Amgen Inc., Boehringer Ingelheim International GmbH, Corcept Therapeutics, Merck & Co., Inc., Novo Nordisk Foundation. H.J. Baer: None. B. Scirica: Research Support; Current; Amgen Inc., Novo Nordisk, Merck & Co., Inc., Boehringer Ingelheim International GmbH, AstraZeneca, Milestone, Foresite Labs, Pfizer Inc., Verse. A.J. Blood: Other - Consultant, grant support; Current; AstraZeneca. Research Support; Current; Merck & Co., Inc. Other - Consultant and grant support; Current; Boehringer Ingelheim International GmbH. Consultant; Ended; Alnylam Pharmaceuticals, Inc. Consultant; Current; Medscape. Other - Consultant and grant support; Ended; Novo Nordisk. Consultant; Current; Milestone Therapeutics, Corcept Therapeutics. Stock/Shareholder; Current; AIwithCare, Knownwell, Signum Technologies.
Zitieren
APA
OSTROMINSKI, J., WAGHOLIKAR, K. B., FALAHEE, B. E., TUCCI, M., NICHOLS, H., CANNON, C., PLUTZKY, J., BAER, H. J., SCIRICA, B., & BLOOD, A. J. (2026). 2923-LB: A Remote Program for Navigator- and Pharmacist-Led Implementation of Obesity Medications. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2923-lb
Vancouver
OSTROMINSKI J, WAGHOLIKAR KB, FALAHEE BE, TUCCI M, NICHOLS H, CANNON C, et al. 2923-LB: A Remote Program for Navigator- and Pharmacist-Led Implementation of Obesity Medications. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2923-lb
BibTeX
@article{OSTROMINSKI2026,
author = {OSTROMINSKI, JOHN and WAGHOLIKAR, KAVISHWAR B. and FALAHEE, BRYN E. and TUCCI, MICHELA and NICHOLS, HUNTER and CANNON, CHRISTOPHER and PLUTZKY, JORGE and BAER, HEATHER J. and SCIRICA, BENJAMIN and BLOOD, ALEXANDER J.},
title = {2923-LB: A Remote Program for Navigator- and Pharmacist-Led Implementation of Obesity Medications},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2923-lb}
}
EUVIMED